[INQ. NO. 2107C25] Bondex Inj is osteoporosis medicine for postmenopausal females made with Ibandronate. It comes in prefilled syringes, thus solving the disadvantages posed by the existing oral drugs, such as cumbersome intake methods and side effects to the stomach.
It also solved the drug compliance problem occurring from frequent dosage. It is receiving attention as the most frequently prescribed injection in the osteoporosis market.
Mixed Dyslipidemia Medicine
Atmeg Combigel is Korea’s first compound-mixed dyslipidemia medicine in combigel dosage form that combines omega-3 soft capsules with Atorvastatin tablets. It has an oil-resistant coating that keeps Atrovastatin stable, and its protective film protects omega-3 and Atorvastatin.
Its efficacy in improving non-HDL-C value and TG of complex dyslipidemia patients and stability has been proven through clinical research.
Korea United Pharm Inc., established in 1987, has been focusing on developing foreign markets since its establishment. It has established local entities in Vietnam, the Philippines, Thailand, Indonesia, and other major foothold countries and is realizing the dream of becoming a multinational Korean-owned pharmaceutical company.
Korea United Pharm Inc. is recognized as Korea’s top-level research-focused pharmaceutical company that actively invests more than 10% of its annual revenues in R&D. The company is focusing on the development of incrementally modified drugs (IMDs).
The company was recognized as an ‘innovative pharmaceutical company’ in 2012 and selected as one of the ‘World Class 300 Project’ companies in 2014, as a result of such efforts. The company’s technological advancement and the excellence of the company’s products are recognized both internally and externally, as its IMDs, Cilostan CR and Clanza CR, were designated as ‘World’s Top-class Next-generation Products’ by Korea’s Ministry of Trade, Industry and Energy in 2016.
Korean-Products.com | Blog Magazine of Korean products, brands and Goods